Prevalence of asymptomatic malaria parasitaemia following mass testing and treatment in Pakro sub-district of Ghana

Ignatius Cheng Ndong
Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana

Corresponding Author
ORCiD: 0000-0003-1073-3956

Daniel Okyere
Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon

Juliana Yartey Enos
Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon

Benedicta Ayiedu Mensah
University of Ghana Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon

Alexander Kwadwo Nyarko
Noguchi Memorial Institute for Medical Research, College of Health Science, University of Ghana, Legon

Alfred Amambua-Ngwa
London School of Hygiene and Tropical Medicine Department of Population Health

Corinne Simone C. Merle
Special Programme for Research and Training in Tropical Diseases

Kwadwo Ansah Koram
Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon

Collins Kwadwo Ahorlu
Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon

Benjamen Abuaku
Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana

DOI: 10.21203/rs.2.12320/v1

SUBJECT AREAS  Health Policy

KEYWORDS  malaria, MTTT, malaria asymptomatic parasitaemia, children
Abstract

Background: Global efforts to scale-up malaria control interventions are gaining steam. These include the use of Long-Lasting Insecticide Nets, Intermittent Preventive Treatment and Test, Treat and Track (T3) using ACTs. Intermittent preventive treatment of children (IPTc) in Ghana has demonstrated a parasite load reduction of 90%. However, unanswered questions include – whether mass treatment of population sub-groups such as IPTc could be scaled-up to whole populations as in mass testing, treatment and tracking (MTTT)? What is needed to implement MTTT at scale? Can MTTT reduce asymptomatic parasitaemia levels in children under 15? And whether MTTT of populations complemented by community-based management of malaria (CBMm) using volunteers could be an effective strategy for malaria control at a lower cost.

Methods: A population of 5,000 asymptomatic individuals in seven communities in the Pakro sub-district of Ghana participated in this study. A register was developed for each community following a census. MTTT engaged trained community-based health volunteers (CBHVs) who conducted house-to-house testing using RDTs every four months and treated positive cases with ACTs. Between interventions, CBMm was done on symptomatic cases.

Results: MTTT Coverage was 98.8% in July 2017 and 79.3% in July 2018. Of those tested, asymptomatic infection with malaria parasites reduced from 1,795 (36.3%) in July 2017 to 1,303 (32.9%) in July 2018. Implementing MTTT significantly averted asymptomatic parasitaemia by 24% from July 2017 to July 2018 after adjusting for age, ITN use and temperature (OR=0.76, CI=0.67, 0.85 p ≤ 0.001). In comparison, treatment of symptomatic patients at the Health Centre reduced parasitaemia by
9% over the same period which was however, not statistically significant (OR=0.91, CI=0.67, 1.38 p = 0.672). A total of 223 (5.1%) cases were averted in children under 15 years (X² = 9.7, p < 0.002). An important observation was a decrease in hospital attendance, which negatively affected the internally generated funds (IGF) scheme of the participating health facilities.

Conclusion: This study has demonstrated that implementing MTTT was feasible and could reduce prevalence of malaria asymptomatic parasitaemia in children under 15 years of age. Furthermore, the use of CBHVs could ensure high coverage at lower cost.

Background

Over the last two decades, tremendous progress has been made in the fight against malaria achieving significant reduction in the global prevalence by 18%, mortality and mobility in all age groups declined by 48%, while mortality in children 2-10 years declined by 33% [1, 2]. This has resulted from a step-up in control efforts toward it’s elimination [3]. Despite the recorded successes, malaria still remains a significant public health threat especially in endemic communities in Africa, where most of the morbidity and mortality occurs. Moreover, current evidence suggests a surge in prevalence and mortality between 2010 and 2016 in some parts of sub-Saharan Africa [4]. In order to change the present dynamics, there is a need to employ alternative intervention strategies such as mass testing, treatment and tracking (MTTT) [3, 5]. Malaria mass drug administration (MDA) is an effective and well-known strategy that has been found to drastically reduce prevalence, reverse mortality trends and led to elimination in specific areas [6-13]. MDA was used in the malaria eradication efforts at different points in history between 1950s—1970s [6,
Though initially successful, these efforts failed due to several factors including the following; i) not all the regions of the world were covered. For instance, the Africa region was not part of the elimination strategy; ii) lack of sustainability as local governments did not have ownership; iii) poor feasibility as the local communities were not well informed about the interventions, and iv) resistance to both antimalarial drugs and insecticides [15–19].

The factors that influenced the effectiveness of MDA remain broadly valid today with similar, malaria epidemiology [15, 20, 21]. The renewed interest in malaria MDA has stimulated an interest in mass testing, treatment and tracking (MTTT) in order to limit unnecessary drug pressure and resistance development. MTTT may face similar challenges such as ineffective coverage and a lack of community ownership etc., requiring the following questions to be addressed; what level of community coverage can be achieved through MTTT? Can MTTT reduce malaria incidence? What will be the impact of MTTT on malaria-related hospital visits? We demonstrated in our earlier report that communities are willing to fully engage and take ownership of the MTTT interventions [22].

In the context of present day challenges, attempts have been made to formulate achievable malaria interventions such as passive testing, treatment and tracking (T3) of symptomatic cases at health facilities (standard of care), providing whole populations with long lasting insecticidal net (LLIN), intermittent preventive treatment in children (IPTc) and pregnant women (IPTp) and seasonal chemoprevention of malaria (SCM) in sub-Sahara Africa [1, 23]. Today, these interventions mostly target passive cases detected or vulnerable groups such as pregnant women and children [24]. Though they have been shown to drastically reduce malaria prevalence, they remain insufficient in meeting the goal of reducing
the prevalence of malaria to elimination levels. Malaria elimination is still far from being realistic in some endemic communities especially in Africa, under the present dispensation [16]. This is partly due to the fact that asymptomatic parasite carriage, not specifically targeted by most interventions, remains the bedrock that fuels transmission [3]. Without a strategy to significantly reduce asymptomatic parasite carriage, transmission seems to remain unperturbed despite tremendous achievements in treating confirmed febrile malaria cases with effective drugs [25, 26]. Given that cost is a major limitation for implementing MDA of malaria, MTTT is being proposed as an alternative strategy to target asymptomatic individuals, mitigate the effect of resistance development as well as limit unnecessary drug pressure on those who are not carrying the parasite [27, 28]. Attempts to implement mass treatment in endemic communities (seasonal malaria chemoprevention [SMC]) are presently limited to children under 5 in the Sahelian region of Africa. Seasonal Malaria Chemoprevention has been shown to reduce the burden of malaria in children below 5 years in Senegal, Mali and Burkina Faso and has further been proven to be affordable if extended to 10 year old children [23, 29–32]. While SMC has targeted the Sahelian region with marked seasonal transmission, strategies for reducing malaria parasitaemia towards elimination in other endemic transmission areas of Africa, which cover the broader population are needed.

Currently, symptomatic malaria still constitutes 38% of outpatient consultation in hospitals in Ghana, while asymptomatic malaria parasitaemia carriage is 25% in children under 15 and above 40% in school-age children [33–36]. Ghana adopted artesunate and amodiaquine as first line drugs for the treatment of malaria since 2006. It also adopted the T3 strategy in 2010, however, the return rate for malaria
patients post-treatment is still below half [37]. Other drug interventions have included the implementation of IPTc complemented by community management of malaria in coastal communities, which resulted in a reduction of asymptomatic parasitaemia by 90% in children under 5 [38]. However, there are a number of unanswered questions, including: whether MTTT intervention could be scaled-up to the entire population since asymptomatic carriage is higher in adults who have developed partial immunity or premunition [39, 40]? What are the challenges to scaling up the intervention to the adult population? What effect MTTT would have on the prevalence of symptomatic parasitaemia in the short-term? In this article, we report findings on MTTT implementation across seven communities in the Pakro sub-district of Ghana over a period of one year, hypothesizing that implementing MTTT complemented by CBMm could reduce the rate of asymptomatic parasitaemia.

Methods

Study Area
Pakro is one of five sub-districts in the Akwapim south district health directorate (DHD) in the Eastern region of Ghana [41]. The Akwapim south district lies within the semi-equatorial climatic region, and experiences two rainfall seasons in a year with an average rainfall of 125cm to 200cm. The first rainy season begins from May to June with the heaviest rainfall in June, whilst the second rainy season begins from September to October. According to the Ghana Statistical Service (GSS), the average household size in the Akwapim South district is 4.0 whilst the average number of households per house or compound is estimated to be 1.6 [42]. The Pakro sub-district has an estimated population of 7,889 and is bounded to the east by Akwapim North district; to the north by Ayensuano district; and to the west by Nsawam Adoagyiri Municipality. The sub-district is made up of 22 communities, and has 3 health care facilities (1 Health Centre and 2 Community-based Health Planning Service (CHPS) compounds) [41]. Due to limited resources, seven communities were selected for this study; Abease Newsite, Fante Town, Zongo (Adjenase/Kweitey), Piem/odumsisi, Adesa, Sacchi/Tabankro and Odumtokro. These communities had relatively higher population densities. The Pakro Health Centre is one of the thirty sentinel sites for monitoring malaria prevalence in the country coordinated by the Noguchi Memorial Institute for Medical Research (NMIMR). Malaria parasite positivity rate at the Pakro Health Centre was 45.7% in 2014 while anaemia among pregnant women at 36 weeks of gestation was 21% [41]. To
undertake this study, fourteen Community-Based Health Volunteers (CBHVs) were specifically recruited and trained for MTTT on the use of RDT test kits, treatment following the malaria treatment guidelines, and follow-up as well as reporting adverse events. CBHVs are community members without a health background.

Selection of Communities

In consultation with the district health service, we considered a 5km radius from the health facility and all 7 communities located within that zone were selected.

Study participants

The entire population of about 5,000 from the seven selected communities in Pakro sub-district was enrolled in the study. This population size was obtained through the household census. Community engagement activities to sensitize the chiefs and the general population was conducted at the beginning of the study through meetings and durbars [33, 43]. All households were numbered, and community registers developed to ensure tracking of the participants. Each household was given a unique identification code. Each individual within the household was assigned a code that links them to a particular household and community. After obtaining parental informed consent, the children were enrolled but individual assent and consent was obtained from the adolescents and adults. (Fig. 1)

Inclusion criteria

All community members were included in the study population. Willingness to participate was evident upon completion and signing of a consent form by the individual, parent or guardian in the case of children.

Exclusion criteria

If an individual had a life-threatening illness (excluding malaria) he/she was excluded. However, all individuals including those with clinical malaria signs who were present during surveys were tested and when confirmed to carry malaria parasites were treated.

Mass testing, treatment and tracking (MTTT) of the population

The entire population of the selected communities was screened for the presence of malaria parasites using the Ag P.f RDT (SD Bioline, Standard Diagnostics, Republic of Korea) which detects histidine-rich proteins II antigens (HRP-2 Ag) specific to P. falciparum in human blood. The RDTs were obtained from the National Malaria Control Programme (NMCP). All participants confirmed to be carrying malaria parasites were treated using an ACT following the National Malaria Treatment Guidelines [14]. To ensure that participants adhered to treatment and to document adverse events, we followed-up participants at home after treatment on days 1, 2, 3 and 7. Each participant was observed for five minutes after treatment administration to ensure that they retain the drug. For children who vomited within five minutes of taking ACT, the treatment was re-administered as it was assumed that the drug had not been adequately absorbed. The ACTs used in this study were also obtained from the National Malaria Programme (NMCP). The drug regimen was changed at any given time depending on what the NMCP was supplying across the country. For instance, in July 2017, March 2018 and July 2018, we used artesunate-amodiaquine (AA) while in November 2017 we used artemether lumefantrine (AL).
Fig 1: Implementation scheme of MTTT interventions in Pakro. MTTT intervention were conducted every 4 months. Between interventions, the CBHVs conducted community-based management of malaria. The time indicates the intervention periods. This report compares the parasitaemia prevalence at baseline to evaluation.

Timely treatment of suspected febrile malaria cases in the community
To facilitate MTTT, two volunteers from each community were recruited, trained and were provided with the protocol, RDTs and ACTs. Between one MTTT intervention and the next, all children and adults reporting signs and symptoms of malaria were tested by community-based health volunteers (CBHVs) using RDTs. When confirmed to be carrying the malaria parasite, the CBHVs treated the participant promptly using ACTs following the malaria management protocols provided. The research team conducted monthly monitoring visits to interact with CBHVs involved in community-based management to ensure that the protocol was being respected as well as replenish their stocks.

Data collection
To facilitate tracking and improve coverage, a community register was developed. All households were numbered, and each individual assigned a unique number which is linked to a particular household. Communities were divided into neighbourhoods and volunteers were assigned a specific catchment area where they are well known. This allowed the CBHVs to schedule appointments with a particular household head before visiting to collect data. This enabled the CBHVs to come around when most of the household members were at home. In some instances, the CBHVs had to visit the houses more than one time to be able to attend to all the participants.

Following consent, blood was drawn from a finger prick. At baseline, all community participants were tested using RDTs (prevalence survey) before treatment with ACT (intervention), when positive. The data resulting from this work were stored at the Noguchi Memorial Institute for Medical Research. Hospital data was also collected during the intervention months.

Data Management and Analysis
Data was analysed using SPSS (IBM SPSS Statistics 20, United States). The unit of enrolment was the household. Malaria prevalence was reported as proportion of participants confirmed during screening to be carrying the malaria parasite, and they were stratified by demographic variables such as age, sex and community. To determine whether treating asymptomatic parasitaemia had an effect on symptomatic malaria during OPD attendance, hospital data were compared to intervention data. A Chi square statistic was used to compare prevalence of
parasitaemia across age groups, gender and communities at the 95% confidence level (p = 0.05). The p-values represent changes between temporal time points. Also, a regression analysis was conducted to test the effect of factors such as timeline, age, temperature and use of LLIN on the MTTT intervention.

Ethical Consideration

The protocol for this study was reviewed and approved by the Ghana Health Service Ethics Review Committee (GHS-ERC -01/03/17) and the Institutional Review Board (IRB) of the Noguchi Memorial Institute for Medical Research, University of Ghana (054/16-17). All participants signed an informed consent form prior to participating in the study. Community consent was given by the chiefs and elders while households consent was given by the household head or parents/caretakers for children below 18 years. Individual assent was obtained for children 12-17 years old while participants from 18 years old and above provided individual consent.

Results

Coverage

Four MTTT interventions were conducted in (July 2017, November 2017, March 2018 and July 2018). Of the 5,000 participants initially targeted across communities for each intervention, coverage ranged from 77.8% to 98.8% (Table 1). The proportions represent those who were effectively reached and tested. Females made up 50.4% and 52.4% of participants in July 2017 and July 2018, respectively (Table 1). The fluctuation in coverage was largely due to movement of people in and out of the intervention area, and the proportion represents those who were effectively reached. If a household was visited three times and the participants could not be contacted, (s)he was considered not available for the survey/intervention or reported to have moved.

Asymptomatic parasitaemia prevalence

Considering the different time points across the intervention period, asymptomatic malaria parasite carriage was found to be 36.3% in July 2017, 22.1% in November 2017, 23.2% in March 2018 and 32.9% in July 2018. These observations reflect the seasonality of malaria in the district and across the country.

Table 1: Parasite carriage across different communities at different time points in the Pakro sub district
Asymptomatic parasite carriage across communities recorded the highest prevalence per time point of 41.2%, 28.3%, 31.9% and 42.1% for July 2017, November 2017, March 2018 and July 2018 respectively (table 1). Comparative analysis between the two time points, July 2017 to July 2018 revealed a decline in asymptomatic parasite carriage of 492 (3.4%) cases ($X^2 = 11.71$, df = 1, p=0.001) (Table 1). Parasite carriage significantly declined in both Abease and Fante Town between July 2017 and July 2018 (p<0.0001 and p=0.037 respectively). Except for Sachi/Tabankro where an observed increase in parasite carriage was not significant in July 2018, the decline in parasite carriage in the other communities was not significant (Table 2). A significant association was observed between communities and the asymptomatic parasitaemia prevalence (p=0.000).

The highest rate of decline in parasitaemia carriage, was observed in Abease while the lowest rate of decline was observed in Adesa. It is not clear what accounted for the heterogeneity as there were no other interventions in the area at the time of this study. Asymptomatic parasitaemia prevalence from July 2017 and July 2018 significantly decreased in both children and adults (p=0.002 for <15 children and p=0.001 for ≥15 years) (Table 2). As per age group, asymptomatic parasitaemia prevalence significantly declined in the age groups 5-14 and 15-45 years, but the decline was marginally significant in the age group 1-4. This decline in parasitaemia was not significant in the age groups 46-65 and >65 years. The age group <1 year old observed an increase in parasitaemia prevalence between July 2017 and 2018 which not significant.

Table 2: Univariate analysis of effect of MTTT interventions on prevalence of asymptomatic malaria parasitaemia over the time points July 2017 and 2018.
| Characteristics          | July 2017 Survey | July 2018 Survey | $\chi^2$ value | F  |
|-------------------------|-----------------|-----------------|---------------|----|
| Community               |                 |                 |               |    |
| Abease                  | 282 (31.8)      | 161 (22.3)      | 17.1          |    |
| Adesa                   | 158 (38.9)      | 121 (35.4)      | 1             |    |
| Adjanase                | 514 (38.3)      | 387 (37.3)      | 0.2           |    |
| Fante Town              | 543 (35.5)      | 392 (31.7)      | 4.4           |    |
| Odomtokro               | 101 (41.2)      | 63 (35.0)       | 1.7           |    |
| Piem                    | 80 (36.4)       | 57 (35.6)       | 0             |    |
| Sachi/Tabankro          | 117 (37.7)      | 122 (42.1)      | 1.17          |    |
| All Communities         | 1795 (36.3)     | 1303 (32.9)     | 11.71         |    |
| Age_group (years)       |                 |                 |               |    |
| 0 - 11 months           | 14 (25.0)       | 22 (38.6)       | 2.4           |    |
| 1 - 4 years             | 270 (49.9)      | 216 (44.0)      | 3.6           |    |
| 5 - 14 years            | 759 (54.7)      | 582 (49.3)      | 7.5           |    |
| 15 - 45 years           | 585 (28.0)      | 360 (23.6)      | 8.5           |    |
| 46 - 65 years           | 129 (20.2)      | 97 (17.8)       | 1             |    |
| > 65 years              | 38 (16.9)       | 26 (15.2)       | 0.2           |    |
| Total # of <15          | 1043 (52.6)     | 820 (47.5)      | 9.7           |    |
| Total # of ≥15          | 752 (25.4)      | 483 (21.6)      | 10.4          |    |
| Mean Temperature        | 36              | 36.2            |               |    |
| Use ITN                 |                 |                 |               |    |
| No                      | 2974 (65.1)     | 380 (32.5)      | 0.0012        | <  |
| Yes                     | 200 (54.5)      | 923 (33.0)      |               |    |

** Significance level at $\alpha = 0.05$

All percentages represent proportions of parasite carriage compared to the population tested. The comparison is made only between July 2017 and July 2018 which depicts the same season.

A logistic regression was performed to determine whether the intervention reduced malaria asymptomatic parasitaemia in all the communities. Age, use of ITN and ambient temperature were predictors of malaria parasitaemia at the univariate level ($\alpha = 0.05$) (Table 3) and were included as confounders in predicting the magnitude of effect of the intervention on malaria parasitaemia prevalence. The intervention reduced parasitaemia by 24% a year, after the mass treatment in July 2018, following adjusting for confounders (OR=0.76, CI=0.67, 0.85 p value≤0.001) and by 9.4% a year, unadjusted. A unit increase in age reduces malaria prevalence by 3%.
after adjusting for confounders (OR=0.97, CI=0.97, 0.97, p value≤0.001). The use of
ITN was not a statistically significant predictor of malaria parasitaemia prevalence
after adjusting for confounders (OR=1.11, CI=0.98, 1.26, p value≤0.001). The
implementation of MTTT reduced symptomatic parasitaemia by 9% from July 2017 to
July 2018 after adjusting for age, though not statistically significant (OR=0.91,
CI=0.67, 1.38 p value = 0.672) (Table 4).

Table 3: Logistic Regression

| Characteristics     | Unadjusted OR | P value | Adjusted OR | P value |
|---------------------|---------------|---------|-------------|---------|
| Timeline            |               |         |             |         |
| July 2017 survey    | Ref           | 0.001   | Ref         | <0.001  |
| July 2018 survey    | 0.86 (0.78, 0.94) | <0.001 | 0.76 (0.67, 0.85) | <0.001  |
| Age (years)         | 0.97 (0.97, 0.97) | <0.001 | 0.97 (0.97, 0.97) | <0.001  |
| Mean Temperature    | 1.19 (1.14, 1.25) | <0.001 | 1.19 (1.12, 1.26) | <0.001  |
| ITN Use             |               |         |             |         |
| No                  | Ref           | 0.034   |             | 0.086   |
| Yes                 | 0.92 (0.87, 0.99) |       | 1.11 (0.98, 1.26) |        |

Asymptomatic versus symptomatic parasite carriage

Records show that in July 2017, the Pakro Health Centre consulted 4.4% (219/4941)
of the entire study population who became febrile, 1.9% (96/4,941) of these
confirmed to be positive for malaria. This means that 43.8% (96/219) of all those
presenting with fever were positive for symptomatic parasitaemia carriage in July
2017 and were treated. In July 2018, the Health Centre consulted 5% (197/3,966) of
the population that became febrile, 2% (78/3,966) were confirmed to be positive for
malaria. Prevalence of symptomatic parasitaemia among study participants
presenting with fever was 39.6% (48/197) representing a 4.2% reduction in
symptomatic parasitaemia between July 2017 and July 2018 (Table 5).

Implementing MTTT interventions significantly reduced asymptomatic parasite
carryage by 24% (OR = 0.76, CI = 0.67, 0.85 p = ≤0.001) after adjusting for age,
use of ITN and ambient temperature compared to an insignificant reduction of 9%
(OR = 0.0.91, CI = 0.67, 1.38, p = 0.672) in confirmed symptomatic malaria cases
who attended the health facility over the same period (Table 4). This demonstrates
that implementing MTTT interventions could reduce the asymptomatic malaria
prevalence, which may not necessarily be reflected to the same degree in the
outpatient consultations within the first year.

Table 4: Logistic regression for symptomatic cases
| Characteristics          | Unadjusted OR (CI) | P value | Adjusted OR (CI) | P value |
|--------------------------|--------------------|---------|-----------------|---------|
| **Timeline**             |                    |         |                 |         |
| July 2017 survey         | Ref                | 0.381   | Ref             | 0.672   |
| July 2018 survey         | 0.83 (0.57, 1.24)  | 0.91 (0.67, 1.38) |         |         |
| **Age_group (years)**    |                    |         |                 |         |
| 0 - 11 months            | Ref                | <0.001  | Ref             | <0.001  |
| 1 - 4 years              | 1.72 (1.41, 2.11)  | <0.001  | 0.67 (0.64, 6.91) | 0.53    |
| 5 - 14 years             | 3.31 (2.70, 4.08)  | <0.001  | 1.62 (0.44, 5.92) | 0.469   |
| 15 - 45 years            | 0.72 (0.59, 0.89)  | 0.002   | 0.54 (0.15, 1.86) | 0.328   |
| 46 - 65 years            | 0.46 (0.38, 0.58)  | <0.001  | 0.31 (0.08, 1.16) | 0.082   |
| > 65 years               | 0.49 (0.40, 0.61)  | <0.001  | 0.34 (0.09, 1.23) | 0.111   |

Table 5: Comparative analysis of asymptomatic and symptomatic prevalence in the Pakro sub-district

|                     | MTTT Data (Asymptomatic parasitaemia) | Hospital Data for clinical malaria (symptomatic parasitaemia) |
|---------------------|---------------------------------------|-------------------------------------------------------------|
|                     | RDT + | Total tested | % | RDT + | Total OPD attendance |
| Jul-17              | 1,795 | 4,941 | 36.3 | 96 | 219 |
| Jul-18              | 1,303 | 3,966 | 32.9 | 78 | 197 |

Confirmed parasitaemia was found to have decreased across all the age groups except the 0-11 months and 15-45 years age group where the proportion increased. However, neither the observed increase nor decrease in parasitaemia was significant in all age groups (Table 5).

Table 5: Confirmed symptomatic parasitaemia across all age groups N (%)
| Age group     | July 2017 Survey | July 2018 Survey | $\chi^2$ value | P Value |
|---------------|------------------|------------------|----------------|---------|
| 0 - 11 months | 2 (40.0)         | 4 (66.7)         | 0.7822         |         |
| 1 - 4 years   | 28 (46.7)        | 16 (42.1)        | 0.1957         |         |
| 5 - 14 years  | 24 (72.7)        | 17 (58.6)        | 1.3713         |         |
| 15 - 45 years | 26 (35.6)        | 23 (45.1)        | 1.1293         |         |
| 46 - 65 years | 6 (33.3)         | 11 (24.4)        | 0.5156         |         |
| > 65 years    | 10 (33.3)        | 7 (25.0)         | 0.4854         |         |
| Total # of <15| 54 (55.1)        | 37 (50.7)        | 0.3279         |         |
| Total # of ≥15| 42 (34.7)        | 41 (33.1)        | 0.0741         |         |

Discussion

Mass testing, treatment and tracking of the entire population in an endemic area such as Pakro is suggested to contribute to a decline in asymptomatic malaria parasite carriage. Population coverage of more than 75% could be achieved during MTTT interventions by using CBHVs [6]. Though some level of population movement in and out of the study communities was observed, the communities are more or less established with a relatively low degree of migration. This is promising for malaria elimination efforts through MTTT in endemic areas [11]. However, there is a need to validate these findings in a larger population by scaling up the intervention. The reasons for variation in parasite carriage and impact of MTTT across communities is not clear. Malaria prevalence across the communities was heterogeneous and we suspect that differences in environmental factors which play a role in malaria transmission in the locality could be contributing to the heterogeneity in outcome. Abease and Odomtokro are higher in altitude while the rest of the communities are low lying, forming part of the flood plain of the Densu River, which could be affecting the continuous transmission in the area. Our results suggest that if MTTT is abandoned without ensuring that the parasite is effectively cleared from the community, transmission could easily be re-established to previous levels within a short time [6]. This is because the drop in asymptomatic
parasitaemia of 3.4% between the two time points under consideration was relatively low.

Observing more cases of asymptomatic parasite carriage through MTTT compared to symptomatic cases through the standard of care (T3) at the health facilities is of public health relevance. This observation suggests that malaria control and intervention strategies should consider asymptomatic parasitaemia as a public health concern and a major hindrance to malaria elimination efforts. As 94% of the malaria asymptomatic carriers do not become febrile should probably suggest that malaria elimination programmes in endemic communities such as Ghana may require a change in strategy from targeting symptomatic to asymptomatic parasite clearance. While clearing of asymptomatic parasitaemia can lead to a decline in transmission over time [3] and consequently reflect in a reduction in malaria-related hospital attendance, the effect may or may not be very visible in the first years of MTTT implementation. This is more-so if malaria-related visits is considered as a lone indicator rather than all-cause hospital visits [17, 44]. This finding is in sharp contrast to the report by Halliday et al.,[45] who reported the absence of an impact on health following the intermittent preventive treatment of school age children in Kenya. It seems a public health dilemma, that in Pakro less than 10% of the malaria parasite carriers actually visit health facilities for clinical management. Despite this observation, the health facility complained that during the MTTT interventions, there was a drastic drop in the number of febrile cases attending the facility. This was further confirmed by the perceptions of the community members during focus group discussions, when they stated that their level of hospital attendance had reduced during that period [22]. It has been reported that a decline in malaria episodes in Kenya was accompanied by a concurrent decline in bacterial diseases
The observations in Kenya could potentially explain our observations in Pakro District, though the rate of bacterial causes of hospitalizations was not determined in this study.

Also, since malaria constitute the bulk of OPD attendance, eliminating malaria in endemic communities could become another public health dilemma as other programmes seem to depend on revenue generated from malaria visits to run the health facilities [47]. As reported in our earlier publication, implementing MTTT led to a decrease in the internally generated revenue of the Pakro Health Centre [22].

As expected there was decline in asymptomatic malaria for both under 15 years and those above 15 years. The group aged above 15 years was observed to have the highest asymptomatic parasite carriage and incidentally is the group that does not usually become febrile. Therefore, reducing the parasite carriage in this age group could possibly propel a decline in transmission. Consequently, this could lead to a decline in the burden of febrile malaria in the children under 15, especially among the under-5 children who have not yet developed partial immunity to the malaria parasite [3, 25, 26, 33, 47]. There were no significant differences in the symptomatic burden in both children <15 and adults above 15 years between July 2017 and July 2018. There is need for more data in order to draw meaningful conclusions from these observations.

Limitations

Some of the limitations of this study include that fact that i) the time of the study was short, and therefore more robust data needs to be collected for meaningful conclusions to be made. ii) The effect of community based management of malaria by the CBHV was not estimated. This could have thrown more light on the impact of
MTTT. iii) The parasite status of participants who move out of the study communities between interventions was not assessed upon return to determine whether they returning with new infection infected. iv) We use only RDTs as testing tool. This means we might have missed participants with low density parasitaemia which could have improve the results.

Conclusions

The findings of this study suggest that MTTT contributed to a decline in asymptomatic malaria parasite carriage in the population of the Pakro sub-district in Ghana. It is feasible to attain more than 75% coverage of MTTT complemented by community-based management of malaria in Pakro and similar endemic areas. It also demonstrates that most of the parasite carriers in an endemic community do not become febrile, thus, more people can be cleared of the parasite through MTTT than the current facility-based consultations or standard of care (T3). Furthermore, the results revealed that in the early stages of implementing MTTT, reduction in asymptomatic parasite carriage in the community may or may not immediately be reflected in malaria-related attendance at health facilities in the short term.

Abbreviations

AA: Artesunate Amodiaquine
ACT: Artemisinin-based Combination Therapy
AL: Artemether Lumefantrine
CHPS: Community-based Health Planning and Services
CBHV: Community-Based Health Volunteer
ERC: Ethics Review Committee
FGD: Focus Group Discussion
GHS: Ghana Health Service
GSS: Ghana Statistical Service
LLIN: Long Lasting Insecticidal Nets
IRB: Institutional Review Board
IRS: Indoor Residual Spraying
IPTc: Intermittent Preventive Treatment in children
IPTp:
Intermittent Preventive Treatment in pregnant women MTTT: Malaria Testing, Treatment and Tracking NMCP: National Malaria Control Programme T3: Test Treat Track WHO: World Health Organisation.

Declarations

Ethics approval and consent to participate

The protocol for this study was reviewed and approved by the Ghana Health Service Ethics Review Committee (GHS-ERC -01/03/17) and the Institutional Review Board of the Noguchi Memorial Institute for Medical Research, University of Ghana (054/16-17). All participants signed an informed consent form prior to participating in the study.

Consent to publish

Not applicable

Availability of data and materials

The data analysis is available in the Department of Epidemiology, Noguchi Memorial Institute for Medical Research and can be made available upon reasonable request.

Competing interests

The authors declare that they have no competing interests.

Authors’ Contribution

C: conceived the study and experimental design, data collection, analysis and preparation of the manuscript. DO: was involved in the implementation and writing of the manuscript, JYE: was involved in design of study and preparation of the manuscript. BAM: conducted the statistical analysis. ANA: was involved in the design and reviewed the manuscript. CSM: was involved in the design and reviewed the manuscript. AN: was involved in the implementation of the study and preparation of the manuscript. BA was involved in the design and reviewed the manuscript. KAK was involved in the design, implementation and writing of the manuscripts. All authors have read and approved the manuscript.

Funding

Financial support for this study was provided by the WHO Special Programme for Research and Training in Tropical Diseases (TDR) Postdoctoral Fellowship programme in Implementation Research. The TDR played no role in the design of the study and data collection, analysis, and interpretation of data for this study. The authors alone are responsible for the views expressed in this publication and they
do not necessarily represent the decisions, policies or views of their institutions.

Availability of data and materials

The datasets used during the study are available from the corresponding author on reasonable request.

Acknowledgement

We are grateful to the National Malaria Control Programme, the Regional and District Health Administration for collaborating with the study. We greatly appreciate the contribution of Rev. Richard Yeboah, Mr. Prosper Agbagbah, Dr. Prince Baah Van-ess, Mrs. Eunice Abuaku and Mr. Appiangye Buabeng. We sincerely thank the community volunteers who delivered the interventions to the community. We also thank the staff of the Epidemiology Department, Noguchi Memorial Institute for Medical Research, University of Ghana for their field support. Many thanks to the chiefs, elders and the entire population of the study communities, especially the caregivers and children for participating in the study, without whom there would have been no study.

Author’s information

Ignatius Cheng Ndong (PhD) is with the Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of health Sciences, University of Ghana and Department of Biochemistry Faculty of Science, Catholic University of Cameroon (CATUC), Email: ndongicheng@yahoo.com, Ncheng@noguchi.ug.edu.gh, Daniel Okyere (BA), Juliana Y. Enos (DrPH), Benedicta A. Mensah (MSc), Kwadwo A. Koram ((PhD), and Collins S. Ahorlu (PhD), Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of health Sciences, University of Ghana, Email: Dokyere@noguchi.ug.edu.gh, Jenos@noguchi.ug.edu.gh, Bmensah@noguchi.ug.edu.gh, kkoram@noguchi.ug.edu.gh, cahorlu@noguchi.ug.edu.gh, Alexander A. Nyarko (PhD) Department of Clinical Pathology, Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, College of health Sciences, University of Ghana, Email: Anyarko@noguchi.ug.edu.gh, Alfred Amambua-Ngwa (PhD), Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine, Email: angwa@mrc.gm, Corinne Simone C. Merle (PhD): Special Programme for Research & Training in Tropical Diseases (TDR), World Health Organization, Geneva, Email: merle@who.int

References

1. Bhatt S, Weiss D, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes C, Henry A, Eckhoff P: The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 2015, 526:207.
2. WHO: *World malaria report 2014. Geneva: WHO; 2014*. Google Scholar 2016.

3. Lindblade KA, Steinhardt L, Samuels A, Kachur SP, Slutsker L: *The silent threat: asymptomatic parasitemia and malaria transmission*. Expert review of anti-infective therapy 2013, **11**:623-639.

4. WHO: *World malaria report 2016. Geneva: World Health Organization; 2016*. 2017.

5. Ndong IC, van Reenen M, Boakye DA, Mbacham WF, Grobler AF: *Trends in malaria admissions at the Mbakong Health Centre of the North West Region of Cameroon: a retrospective study*. *Malaria Journal* 2014, **13**:328.

6. Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, Penny MA, Gerardin J, White LJ, Chitnis N: *Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study*. *The Lancet Global Health* 2017, **5**:e680-e687.

7. Organization WH: *Mass drug administration for falciparum malaria: a practical field manual*. 2017.

8. Adhikari B, James N, Newby G, von Seidlein L, White NJ, Day NPJ, Dondorp AM, Pell C, Cheah PY: *Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review*. *Malaria Journal* 2016, **15**:523.

9. Crowell V, Briët OJT, Hardy D, Chitnis N, Maire N, Pasquale AD, Smith TA: *Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden*. *Malaria Journal* 2013, **12**:4.

10. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J: *Mass drug
administration for malaria. The Cochrane database of systematic reviews 2013:1.

11. Shekalaghe SA, Drakeley C, van den Bosch S, ter Braak R, van den Bijllaardt W, Mwanziva C, Semvua S, Masokoto A, Mosha F, Teelen K, et al: A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal 2011, 10:247.

12. Song J, Socheat D, Tan B, Dara P, Deng C, Sokunthea S, Seila S, Ou F, Jian H, Li G: Rapid and effective malaria control in Cambodia through mass administration of artesiminin-piperaquine. Malaria Journal 2010, 9:57.

13. von Seidlein L, Greenwood BM: Mass administrations of antimalarial drugs. Trends in parasitology 2003, 19:452-460.

14. Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ, Bousema T, Drakeley CJ, Ghani AC: The Potential Contribution of Mass Treatment to the Control of Plasmodium falciparum Malaria. PLOS ONE 2011, 6:e20179.

15. Organization WH: Mass drug administration, mass screening and treatment and focal screening and treatment for malaria. Geneva, World Health Organization 2015a Reference Source 2015.

16. Koram KA, Ahorlu CK: Towards Effective Disease Control in Ghana: Research and Policy Implications: Volume 2 Other Infectious Diseases and Health Systems. Sub-Saharan Publishers; 2014.

17. Chen I, Clarke SE, Gosling R, Hamainza B, Killeen G, Magill A, O’Meara W, Price RN, Riley EM: “Asymptomatic” malaria: a chronic and debilitating infection that should be treated. PLoS medicine 2016, 13:e1001942.
18. Newby G, Hwang J, Koita K, Chen I, Greenwood B, Von Seidlein L, Shanks GD, Slutsker L, Kachur SP, Wegbreit J: Review of mass drug administration for malaria and its operational challenges. *The American journal of tropical medicine and hygiene* 2015, 93:125-134.

19. Pongvongsa T, Phommasone K, Adhikari B, Henriques G, Chotivanich K, Hanboonkunupakarn B, Mukaka M, Peerawaranun P, von Seidlein L, Day NP: The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroartemisinin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. *Malaria journal* 2018, 17:405.

20. Dierickx S, Gryseels C, Mwesigwa J, O’Neill S, Bannister-Tyrell M, Ronse M, Jaiteh F, Gerrets R, D’Alessandro U, Grietens KP: Factors associated with non-participation and non-adherence in directly observed mass drug administration for malaria in The Gambia. *PLoS One* 2016, 11:e0148627.

21. Silumbwe A, Zulu JM, Halwindi H, Jacobs C, Zgambo J, Dambe R, Chola M, Chongwe G, Michelo C: A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. *BMC public health* 2017, 17:484.

22. Ndong IC, Okyere D, Enos JY, Amambua-Ngwa A, Merle CSC, Nyarko A, Koram KA, Ahorlu CS: Challenges and perceptions of implementing mass testing, treatment and tracking in malaria control: a qualitative study in Pakro sub-district of Ghana. *BMC Public Health* 2019, 19:695.

23. Cissé B, Ba EH, Sokhna C, Ndiaye JL, Gomis JF, Dial Y, Pitt C, Ndiaye M, Cairns M, Faye E, et al: Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-
Randomised Trial. *PLOS Medicine* 2016, **13**:e1002175.

24. Ndong IC, Reenen Mv, Boakye DA, Mbacham WF, Grobler AF: Trends in malaria case management following changes in the treatment policy to artemisinin combination therapy at the Mbakong Health Centre, *Cameroon 2006-2012: A retrospective study*. *Acta Tropica* 2015, **150**:100-106.

25. Bousema JT, Gouagna LC, Drakeley CJ, Meutstege AM, Okech BA, Akim IN, Beier JC, Githure JI, Sauerwein RW: *Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya*. *Malaria journal* 2004, **3**:18.

26. Greenwood B: *Asymptomatic malaria infections—do they matter?* *Parasitology today* 1987, **3**:206-214.

27. Haldar K, Bhattacharjee S, Safeukui I: Drug resistance in *Plasmodium*. *Nature Reviews Microbiology* 2018, **16**:156.

28. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B: Spread of artemisinin resistance in *Plasmodium falciparum malaria*. *New England Journal of Medicine* 2014, **371**:411-423.

29. Maiga H, Lasry E, Diarra M, Sagara I, Bamadio A, Traore A, Coumare S, Bahonan S, Sangare B, Dicko Y, et al: Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali. *PLOS ONE* 2016, **11**:e0162718.

30. Owek CJ, Oluoch E, Wachira J, Estambale B, Afrane YA: Community perceptions and attitudes on malaria case management and the role of community health workers. *Malaria Journal* 2017, **16**:272.

31. Pitt C, Ndiaye M, Conteh L, Sy O, Hadj Ba E, Cissé B, Gomis JF, Gaye O, Ndiaye
J-L, Milligan PJ: **Large-scale delivery of seasonal malaria chemoprevention to children under 10 in Senegal: an economic analysis.** *Health policy and planning* 2017, **32**:1256-1266.

32. Druetz T, Corneau-Tremblay N, Millogo T, Kouanda S, Ly A, Bicaba A, Haddad S: **Impact Evaluation of Seasonal Malaria Chemoprevention under Routine Program Implementation: A Quasi-Experimental Study in Burkina Faso.** 2017.

33. Ahorlu CK, Koram KA, Seake-Kwawu AK, Weiss MG: **Two-year evaluation of Intermittent Preventive Treatment for Children (IPTc) combined with timely home treatment for malaria control in Ghana.** *Malaria journal* 2011, **10**:127.

34. Otupiri E, Yar D, Hindin J: **Prevalence of Parasitaemia, Anaemia and treatment outcomes of Malaria among School Children in a Rural Community in Ghana.** *Journal of Science and Technology (Ghana)* 2012, **32**:1-10.

35. Sarpong N, Owusu-Dabo E, Kreuels B, Fobil JN, Segbaya S, Amoyaw F, Hahn A, Kruppa T, May J: **Prevalence of malaria parasitaemia in school children from two districts of Ghana earmarked for indoor residual spraying: a cross-sectional study.** *Malaria journal* 2015, **14**:260.

36. NMCP: **Annual Report 2015.** *Nationala Malaria Control Programme* 2016, Ghana Health Service.

37. Agandaa SA, Kweku M, Agboli E, Takase M, Takramah W, Tarkang E, Gyapong J: **Implementation and challenges of test, treat and track (T3) strategy for malaria case management in children under five years in the Bongo District, Ghana.** *Clin Res Trials* 2016, **2**:235-241.
38. Ahorlu CK, Koram KA, Seakey AK, Weiss MG: Effectiveness of combined intermittent preventive treatment for children and timely home treatment for malaria control. *Malaria Journal* 2009, 8:292.

39. Greenwood B, Mutabingwa T: *Malaria in 2002*. *Nature* 2002, 415:670-672.

40. Doolan DL, Dobaño C, Baird JK: Acquired immunity to malaria. *Clinical microbiology reviews* 2009, 22:13-36.

41. DHS: *Demographic Health Survey 2014*. *Ghana Statistics Service* 2014.

42. GSS: *Population and Housing Sensors* *Ghana Statistics Service* 2010.

43. Ansah EK, Narh-Bana S, Epokor M, Akanpigbiam S, Quartey AA, Gyapong J, Whitty CJ: Rapid testing for malaria in settings where microscopy is available and peripheral clinics where only presumptive treatment is available: a randomised controlled trial in Ghana. *BMJ: British Medical Journal* 2010, 340.

44. O’Meara WP, Bejon P, Mwangi TW, Okiro EA, Peshu N, Snow RW, Newton CR, Marsh K: Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. *The lancet* 2008, 372:1555-1562.

45. Halliday KE, Okello G, Turner EL, Njagi K, Mcharo C, Kengo J, Allen E, Dubeck MM, Jukes MC, Brooker SJ: Impact of intermittent screening and treatment for malaria among school children in Kenya: a cluster randomised trial. *PLoS medicine* 2014, 11:e1001594.

46. Ja S, Ja B: Mwangi i, et al. relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. *Lancet* 2011, 378:1316-1323.

47. Bousema T, Okell L, Felger I, Drakeley C: Asymptomatic malaria infections: detectability, transmissibility and public health relevance. *Nature*
Figures

Figure 1

Implementation scheme of MTTT interventions in Pakro. MTTT intervention were c